In 2020, Heng and co-workers reported the results of another clinical trial (NCT02349698) investigating CAR-Ts with a humanized scFv against CD19 for the treatment of R/R B-ALL patients (Table 1) [30]. Here, CD19 is linked to acute lymphoblastic leukemia.